Q32 Bio shares are trading higher after the company it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial on Monday, July 13, 2026.

Benzinga Newsdesk www.benzinga.com Positive 93.6%

Neg 0% Neu 0% Pos 93.6%

Comments

No comments yet. Be the first!